The AI Use Case That Healthcare is Overlooking
AI performs best where a problem is well-defined, data-intensive, repetitive and operates at a scale that exceeds human tracking capacity. The supply chain hits all four.
AI performs best where a problem is well-defined, data-intensive, repetitive and operates at a scale that exceeds human tracking capacity. The supply chain hits all four.
Difficult packaging comes with tangible consequences, including lower adherence, higher rates of adverse events, and diminished real-world effectiveness. It can also delay FDA submissions and ultimately, market entry.
Payment friction isn't always obvious. It shows up in extended accounts receivable timelines, increased billing inquiries, and patients who delay payment – not because they're unwilling to pay, but because the process made it harder than it needed to be.
Direct-to-patient (DTP) models create a continuous loop of value, connecting seamless patient and provider experience with the strategic power of branding and data.
It’s time to break down the myths holding the pharmacy sector back, and the emerging realities shaping a new, tech-enabled approach to adherence that blends operational redesign, AI innovation and equity-focused care.
By embracing innovation, optimizing operations and advocating for change, pharmacy leaders can ensure their organizations are not only prepared for the future but are actively shaping it.
At a time when 98 million prescriptions are abandoned due to cost surprises, it’s critical that all four categories of prescription drug prices are available so consumers can determine how to obtain needed medications at the lowest cost.
Temperature-sensitive medications represent one of the most critical operational and regulatory challenges in modern pharmacy management.
A handful of states have issued guidance documents that illustrate how regulators are viewing the IV hydration and IV therapy businesses, which infusion providers should consider as part of their overall compliance monitoring efforts.
A quick conversation about coverage, availability and pricing can help patients make informed decisions.
When control over prescription drug access rests with only a few players, the result is not just market imbalance — it is higher plan costs, increased financial pressures, and ultimately reduced affordability for patients.
The real story isn’t about denial rates or stakeholders acting as villains. It’s about a healthcare system that forces intelligent, well-intentioned professionals to make critical decisions in information silos.
AI can now flag where patients are getting stuck — from enrollment delays to dropped calls — while also enabling new, compliant ways to analyze these interactions at scale. But surfacing the issue is just the first step.